BioSpace News Archive

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by the New England Journal of Medicine (NEJM) of results from the Protocol 5 study (DCLP5) of the International Diabetes Closed Loop (iDCL) trial. Results demonstrated increased time spent in range (70-180 mg/dL) in children ages 6 to 13 years old using the t:slim X2™ insulin pump with Control-IQ

Milestone Scientific Inc. today announced that it will be presenting at The LD 500 Investor conference being held virtually on September 1-4, 2020.

Timber Pharmaceuticals, Inc. today announced that it will be presenting at the LD Micro 500 virtual investor conference on Wednesday, September 2, 2020 at 10:20am ET.

Aditx Therapeutics, Inc.today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3rd at 12:20 PM ET.

ENDRA Life Sciences Inc. (''ENDRA’’) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), is exhibiting at The Digital International Liver Congress (ILC), hosted by the European Association for the Study of the Liver (EASL), Aug. 27-29, 2020.

Bioprinting is a field standing at the intersection of biomedical engineering and regenerative medicine that allows for the controlled manufacturing of 3D structures thanks to a layer-by-layer deposition of biomaterial-based inks (bioinks).

The new multi-year study will seek to understand different aspects of the patient experience with lung cancer to improve treatment options and outcomes

Eurofins Technologies (Paris:ERF) recently launched multiple serological assay solutions to detect antibodies targeted against the Nucleocapsid protein of the novel Coronavirus. Antibody tests can be used to identify individuals who have been previously exposed to the virus and in some cases those who have an active infection. However, simple presence of antibodies in an individual does not guarantee immunity to further infec

DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose used today in the ongoing DRIIV-1b and REVOCAN studies of AsiDNA™ in combination with chemotherapy and PARP inhibitors

Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on the development of first-in-class nanocatalysts for the treatment of bioenergetic failure associated with neurodegenerative diseases, today announced the $42.5 million oversubscribed closing of its Series D equity financing.